全血细胞计数衍生生物标志物与甲索特抗性的关系
Tinatin Chikovani1, Nestan Gvetadze1, Luka Abashishvili2
1Immunology, Tbilisi State Medical University, Tbilisi, GEO.
Cureus
|January 19, 2024
概括
血小板与淋巴细胞比率 (PLR) 可能表明类风湿性关节炎 (RA) 患者对甲状腺素治疗的耐药性. 较高的PLR,ESR和DAS28得分表明抗性RA病例中的炎症更大.
科学领域:
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致关节炎症和损伤.
- 甲托雷克萨特是 RA 的主要治疗方法,但抗药性发生.
- 像NLR,PLR,MLR,SII和SIRI这样的全血细胞计 (CBC) 衍生的生物标志物在各种疾病中被研究,但不是专门用于用甲状腺素治疗的RA患者.
研究的目的:
- 研究CBC衍生生物标志物与新诊断的RA患者中甲状腺抗的关系.
- 为了确定潜在的生物标志物,预测RA中的甲状腺素耐药性.
主要方法:
- 对54名RA患者的分析,分为耐甲铁酸 (MTXR) 和敏感甲铁酸 (MTXS) 组.
- 使用ANOVA,t测试和千平方测试的组之间血液学生物标志物 (NLR,PLR,MLR,SII,SIRI) 和临床评分 (DAS28,ESR) 的比较.
- 皮尔森对生物标志物-DAS28关系的相关性分析和预测能力的ROC曲线分析.
主要成果:
- 与MTXS组相比,MTXR组的血小板与淋巴细胞比率 (PLR) 在统计学上显著增加.
- 在MTXR组中发现了DAS28和NLR,PLR,SII和SIRI之间的显著相关性,但在MTXS组中没有.
- 在MTXR组中观察到较高的DAS28和ESR水平;然而,没有一种生物标志物显示出对治疗结果的预后价值.
结论:
- 血小板与淋巴细胞的比率 (PLR) 可以作为一个潜在的生物标志物来预测某些RA患者群体的甲状腺抗性.
- 升高的PLR,ESR和DAS28得分可能表明,在耐甲铁的RA患者中,炎症状况更严重.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...